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**Value of the data**•Previously unreported longitudinal associations of baseline lipoprotein subclasses with carotid IMT at two follow-up time-points in a large well-characterized cohort of people with T1DM.•May stimulate further research on the clinical utility of lipoprotein subclasses as prognostic markers for cardiovascular disease in diabetes.•May facilitate new therapies to target lipids and lipoprotein classes significantly associated with vascular events in diabetes.

1. Data {#s0005}
=======

The Diabetes Control and Complications Trial (DCCT) examined the effects of intensive diabetes management on the development and progression of diabetic retinopathy [@bib2]. The cohort comprised 1441 T1DM patients aged 13--39 years who were free of overt cardiovascular disease (CVD) at enrollment in 1983--89. In 1994, the Epidemiology of Diabetes Interventions and Complications Trial (EDIC), a longitudinal observational phase of DCCT was initiated to assess the long-term effects of the DCCT intervention on cardiovascular and related complications [@bib3]. Carotid IMT data were obtained at EDIC 'Years' 1 (1994--1996), 6 (1998--2000), and 12 (2004--2006). In addition to conventional lipids, nuclear magnetic resonance (NMR)-determined lipoprotein subclasses have been predictive of CVD in some T1DM studies [@bib4], [@bib5], [@bib6], and were analyzed in this cohort to examine associations with a surrogate of CVD: common and internal carotid IMT.

The baseline characteristics of the participants have been described previously [@bib1]. [Table 1](#t0005){ref-type="table"} shows data on the associations of DCCT baseline standard lipid profiles and NMRLSP with common carotid IMT in men and women at EDIC Years 1 and 6. Generally the data reveal positive associations of conventional LDL-cholesterol and NMR-based total IDL/LDL with IMT, and inverse associations of NMR-based large and medium VLDL subclasses, medium HDL and HDL particle size with IMT, most marked in men.

[Table 2](#t0010){ref-type="table"} shows data on the associations of DCCT baseline standard lipid profiles and NMR-LSP with internal carotid IMT in men and women at EDIC Years 1 and 6. Generally there are positive associations of conventional total, LDL- and non-HDL cholesterol levels with IMT in both men and women, and of NMR-based total IDL/LDL, small LDL and HDL (small)-subclasses with IMT in men only. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provides access to the raw data from the DCCT/EDIC study through the NIDDK Central Repository (<https://www.niddkrepository.org/home/>). This website includes information regarding the data sets that are available, and details of the data request, review, and approval process.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Study subjects {#s0015}
-------------------

The original DCCT cohort comprised 1441 T1DM participants aged 13--39 years at study entry (1983--1989). They had no dyslipidemia or hypertension and were randomly assigned to conventional (*n*=730) or intensive (*n*=711) diabetes treatment [@bib2]. The data included in this article are derived from a sub-set of DCCT participants with available common and internal carotid IMT measurements at EDIC Years 1 and 6. The study was approved by the Institutional Review Boards of MUSC, University of Oklahoma Health Sciences Center (OUHSC), and all participating DCCT/EDIC centers, and written informed consent was obtained from all subjects.

2.2. Ultrasonography and image analysis {#s0020}
---------------------------------------

Common and internal carotid IMT measurements in EDIC have previously been described in detail [@bib7]. Reliability measures for IMT readers at EDIC Years 1 and 6 have been reported previously [@bib8]. In the current sub-study, we examined the longitudinal associations between lipoprotein profiles at DCCT entry (1983--89) and common and internal carotid IMT at EDIC Years 1 and 6.

2.3. NMR Lipoprotein subclass analysis {#s0025}
--------------------------------------

NMR-LSP was determined in first-thaw serum specimens (250 µL) using a 400-MHz proton NMR analyzer at LipoScience Inc. (Raleigh, NC, USA) as described [@bib9]. Lipoprotein subclasses were expressed as molar particle concentrations and defined by particle diameter: VLDL subclasses (large: 60--200 nm; medium: 35--59 nm; small: 27--34 nm), intermediate density lipoprotein (IDL) (23--37 nm), LDL subclasses (large: 21.3--23 nm; small: 18.3--21.2 nm), HDL subclasses (large: 8.9--13 nm; medium: 8.3--8.8 nm; small: 7.3--8.2 nm). Average VLDL, LDL, and HDL particle sizes (nm) were determined by weighting the relative mass percentage of each subclass by its diameter.

2.4. DCCT baseline conventional lipid profiles, HbA~1c~, and other clinical measurements {#s0030}
----------------------------------------------------------------------------------------

Total cholesterol, triglyceride, and HDL-C levels were determined using previously reported enzymatic methods [@bib10]. LDL-C was estimated according to the Friedewald equation. HbA~1c~ was measured by high-performance ion exchange liquid chromatography [@bib11].

2.5. Statistical analysis {#s0035}
-------------------------

Multiple regression analyses were performed to examine correlations of conventional lipids and NMR-LSP at DCCT baseline with common and internal carotid IMT at EDIC Years 1 and 6, stratified by gender. Each lipid/lipoprotein measure was included as an independent variable in the linear model simultaneous with a fixed group of covariates that were measured at DCCT baseline: diabetes duration, smoking (yes/no), DCCT treatment group, body mass index (BMI), urinary albumin excretion rate (AER), and HbA~1c~, statin use and ultrasound imaging device. Two-tailed *p*\<0.05 was considered to be statistically significant. Data were analyzed using SAS/STAT software (Version 9.2; SAS Institute Inc., Cary, NC).

Appendix A. Supplementary material {#s0045}
==================================

Supplementary material

This project was funded by Grants from the National Institutes of Health (R01DK080043) and the American Diabetes Association (7-12-CT-46). DCCT/EDIC has been supported by U01 Cooperative Agreement Grants (1982--93, 2011--2016), and contracts (1982--2011) with the Division of Diabetes Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Disease, and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the Genetic Clinical Research Centers Program (1993--2007), and Clinical Translational Science Center Program (2006-present), Bethesda, Maryland, USA. A complete list of participants in the DCCT/EDIC research group can be found in New England Journal of Medicine, 2011; 365:2366-2376.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.11.036](http://dx.doi.org/10.1016/j.dib.2015.11.036){#ir0010}.

###### 

DCCT baseline lipoprotein profiles vs. common carotid IMT-EDIC Years 1 and 6 (standardized linear regression coefficients[a](#tblt0005-fn1){ref-type="table-fn"}).

Table 1

  Variables                                  **Men (*n*=244)**   **Women (*n*=208)**                                                                         
  ------------------------------------------ ------------------- --------------------- -------------- ----------- -------------- ----------- --------------- ------
  **NMR subclasses**                         Slope (SE)          *P*                   Slope (SE)     *P*         Slope (SE)     *P*         Slope (SE)      *P*
  **Total VLDL and chylomicrons (nmol/L)**   0.02 (0.06)         0.74                  −0.04 (0.05)   0.42        −0.05 (0.07)   0.43        −0.08 (0.07)    0.22
   Large VLDL and chylomicrons (nmol/L)      −0.12 (0.06)        **0.04**              −0.04 (0.05)   0.48        0.01 (0.07)    0.9         −0.1 (0.07)     0.14
   Medium VLDL (nmol/L)                      −0.13 (0.05)        **0.02**              −0.05 (0.05)   0.35        −0.04 (0.07)   0.63        −0.02 (0.08)    0.78
   Small VLDL (nmol/L)                       0.11 (0.06)         **0.049**             −0.02 (0.05)   0.64        −0.05 (0.06)   0.43        −0.08 (0.06)    0.22
  **Total IDL/LDL (nmol/L)**                 0.12 (0.06)         **0.04**              0.15 (0.05)    **0.005**   0.12 (0.06)    **0.04**    0.07 (0.07)     0.33
   IDL (nmol/L)                              −0.06 (0.06)        0.30                  −0.04 (0.05)   0.42        0.06 (0.06)    0.32        0.06 (0.06)     0.36
   Large LDL (nmol/L)                        0.04 (0.06)         0.48                  0.06 (0.05)    0.24        0.14 (0.06)    **0.03**    0.04 (0.07)     0.57
   Small LDL (nmol/L)                        0.09 (0.05)         0.1                   0.1 (0.05)     0.06        −0.09 (0.07)   0.17        0.01 (0.07)     0.90
  **Total HDL (µmol/L)**                     −0.08 (0.06)        0.20                  −0.01 (0.06)   0.87        0.10 (0.06)    0.08        0.02 (0.06)     0.74
   Large HDL (µmol/L)                        −0.11 (0.06)        0.08                  −0.05 (0.06)   0.45        0.16 (0.06)    **0.01**    0.05 (0.07)     0.46
   Medium HDL (µmol/L)                       −0.15 (0.07)        **0.02**              −0.03 (0.06)   0.66        0.004 (0.05)   0.94        −0.03 (0.05)    0.62
   Small HDL (µmol/L)                        0.1 (0.06)          0.09                  0.04 (0.06)    0.52        0.04 (0.06)    0.55        0.03 (0.06)     0.59
  **NMR particle diameter**                                                                                                                                  
   VLDL particle size (nm)                   −0.18(0.06)         **0.001**             −0.03 (0.05)   0.64        0.05 (0.07)    0.51        −0.001 (0.07)   0.98
   LDL particle size (nm)                    −0.05 (0.05)        0.39                  −0.04 (0.05)   0.46        0.06 (0.07)    0.41        0.01 (0.07)     0.85
   HDL particle size (nm)                    −0.15(0.06)         **0.01**              −0.10 (0.06)   0.08        0.14 (0.07)    **0.04**    0.06 (0.07)     0.36
  **Conventional lipids**                                                                                                                                    
   Total cholesterol (mg/dl)                 0.05 (0.06)         0.41                  0.08 (0.05)    0.13        0.06 (0.06)    0.34        0.03 (0.07)     0.63
   Triglyceride (mg/dl)                      −0.07 (0.05)        0.14                  0.07 (0.05)    0.11        −0.15 (0.09)   0.08        −0.15 (0.09)    0.11
   LDL--cholesterol (mg/dl)                  0.11 (0.06)         **0.04**              0.10 (0.05)    **0.049**   0.01 (0.07)    0.90        0.02 (0.07)     0.76
   Non--HDL--cholesterol (mg/dl)             0.07 (0.06)         0.22                  0.09 (0.05)    0.09        −0.02 (0.07)   0.75        −0.001 (0.07)   0.92
   HDL--cholesterol (mg/dl)                  −0.07 (0.07)        0.30                  −0.02 (0.06)   0.72        0.18 (0.06)    **0.003**   0.08 (0.06)     0.18

*P* values in bold if significant (\<0.05).

Models were adjusted for DCCT randomization, albumin excretion rate, HbA~1C~, diabetes duration, body mass index, and current smoking at DCCT baseline (1983--89). The regression models were also adjusted for statin use (any time during the DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 1 and 6 respectively.

###### 

DCCT baseline lipoprotein profiles vs. internal carotid IMT-EDIC Years 1 and 6 (standardized linear regression coefficients[a](#tblt0010-fn1){ref-type="table-fn"}).

Table 2

  Variables                                  **Men (*n*=242)**   **Women (*n*=203)**                                                                        
  ------------------------------------------ ------------------- --------------------- -------------- ---------- --------------- ---------- --------------- ------
  **NMR subclasses**                         Slope (SE)          *P*                   Slope (SE)     *P*        Slope (SE)      *P*        Slope (SE)      *P*
  **Total VLDL and chylomicrons (nmol/L)**   −0.01 (0.07)        0.92                  −0.03 (0.07)   0.67       0.01 (0.06)     0.83       0.06 (0.07)     0.35
   Large VLDL and chylomicrons (nmol/L)      −0.04 (0.07)        0.55                  −0.07 (0.07)   0.33       −0.003 (0.07)   0.97       0.05 (0.07)     0.50
   Medium VLDL (nmol/L)                      0.07 (0.07)         0.28                  0.02 (0.07)    0.80       0.04 (0.07)     0.57       0.01 (0.07)     0.84
   Small VLDL (nmol/L)                       −0.05 (0.07)        0.51                  −0.04 (0.07)   0.55       0.001 (0.06)    0.99       0.06 (0.06)     0.33
  **Total IDL/LDL (nmol/L)**                 0.23 (0.07)         **0.002**             0.14 (0.07)    0.06       0.004 (0.06)    0.95       −0.02 (0.06)    0.74
   IDL (nmol/L)                              0.09 (0.07)         0.22                  0.004 (0.07)   0.96       0.08 (0.06)     0.18       0.09 (0.06)     0.13
   Large LDL (nmol/L)                        0.02 (0.07)         0.75                  0.03 (0.07)    0.61       −0.002 (0.06)   0.97       −0.04 (0.06)    0.52
   Small LDL (nmol/L)                        0.14 (0.07)         **0.04**              0.09 (0.07)    0.21       −0.03 (0.07)    0.65       −0.03 (0.07)    0.65
  **Total HDL (µmol/L)**                     0.09 (0.08)         0.26                  0.07 (0.08)    0.38       −0.02 (0.05)    0.67       −0.09 (0.06)    0.12
   Large HDL (µmol/L)                        0.04 (0.08)         0.63                  −0.07 (0.08)   0.42       −0.03 (0.06)    0.62       −0.03 (0.06)    0.56
   Medium HDL (µmol/L)                       0.10 (0.08)         0.23                  0.02 (0.08)    0.79       −0.03 (0.05)    0.52       −0.06 (0.05)    0.23
   Small HDL (µmol/L)                        0.20 (0.08)         **0.01**              0.09 (0.08)    0.26       0.001 (0.06)    0.99       −0.001 (0.06)   0.99
  **NMR particle diameter**                                                                                                                                 
   VLDL particle size (nm)                   −0.0001 (0.07)      1.00                  −0.06 (0.07)   0.44       0.03 (0.07)     0.66       0.02 (0.07)     0.75
   LDL particle size (nm)                    −0.08 (0.07)        0.25                  −0.03 (0.07)   0.63       0.02 (0.07)     0.75       0.02 (0.06)     0.71
   HDL particle size (nm)                    −0.13 (0.08)        0.08                  0.06 (0.07)    0.35       0.07 (0.06)     0.29       −0.12 (0.08)    0.11
  **Conventional lipids**                                                                                                                                   
   Total cholesterol (mg/dl)                 0.17 (0.07)         **0.02**              0.13 (0.07)    0.07       0.15 (0.06)     **0.01**   0.05 (0.06)     0.44
   Triglyceride (mg/dl)                      0.02 (0.06)         0.76                  0.04 (0.06)    0.51       0.04 (0.09)     0.64       0.06 (0.09)     0.52
   LDL--cholesterol (mg/dl)                  0.17 (0.07)         **0.02**              0.14 (0.07)    **0.05**   0.12 (0.06)     **0.05**   0.04 (0.06)     0.51
   Non--HDL--cholesterol (mg/dl)             0.16 (0.07)         **0.03**              0.12 (0.07)    0.09       0.12 (0.06)     **0.05**   0.05 (0.07)     0.45
   HDL--cholesterol (mg/dl)                  0.05 (0.08)         0.57                  0.04 (0.08)    0.62       0.09 (0.06)     0.12       0.01 (0.06)     0.87

*P* values in bold if significant (\<0.05).

Models were adjusted for DCCT randomization, albumin excretion rate, HbA1C, diabetes duration, body mass index, and current smoking at DCCT baseline (1983--89). The regression models were also adjusted for statin use (any time during the DCCT baseline to EDIC year 12), ultrasound devices, and image readers at EDIC year 1 and 6 respectively.

[^1]: These authors contributed equally to this work.
